421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

Bibliographic Details
Main Authors:	Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Howard Kaufman, Suzanne Thomas, Praveen Bommareddy, Francesca Aroldi, Pablo Nanclares, Lavita Menezes, Selda Samakoglu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors
by: Anna Olsson-Brown, et al.
Published: (2021-11-01)

Two roads for oncolytic immunotherapy development
by: Howard L. Kaufman, et al.
Published: (2019-02-01)

Oncolytic HSV: Underpinnings of Tumor Susceptibility
by: Chase Kangas, et al.
Published: (2021-07-01)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
by: Christian Migliarese, et al.
Published: (2023-06-01)

705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial
by: Dirk Schadendorf, et al.
Published: (2023-11-01)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
by: Nusrat Jahan, et al.
Published: (2021-08-01)

Genetic Modifications That Expand Oncolytic Virus Potency
by: Francisca Cristi, et al.
Published: (2022-01-01)

oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy
by: Upasana Sahu, et al.
Published: (2023-06-01)

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
by: Suzanne Thomas, et al.
Published: (2019-08-01)

The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles
by: Guijin Tang, et al.
Published: (2023-02-01)

Biosafety and biohazard considerations of HSV-1–based oncolytic viral immunotherapy
by: Elizabeth Robilotti, et al.
Published: (2023-09-01)

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
by: Gregory K Friedman, et al.
Published: (2013-02-01)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
by: Praveen K. Bommareddy, et al.
Published: (2019-04-01)

Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.
by: Khaphetsi Joseph Mahasa, et al.
Published: (2017-01-01)

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
by: Praveen K. Bommareddy, et al.
Published: (2019-07-01)

1098 Oncolytic HSV blocking tumor-intrinsic PKR sensitizes glioblastoma to immunotherapy
by: Balveen Kaur, et al.
Published: (2023-11-01)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
by: Laura Menotti, et al.
Published: (2018-06-01)

STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
by: Kazuo Okemoto, et al.
Published: (2013-01-01)

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
by: Marilin S. Koch, et al.
Published: (2020-11-01)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
by: Irene Appolloni, et al.
Published: (2021-08-01)

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1
by: Huy-Dung Hoang, et al.
Published: (2023-03-01)

Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications
by: Akram Alwithenani, et al.
Published: (2023-12-01)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
by: Ifeanyi Kingsley Uche, et al.
Published: (2021-06-01)

Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability
by: Faith Howard, et al.
Published: (2022-06-01)

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability
by: Edward M. Kennedy, et al.
Published: (2020-09-01)

Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus
by: Jana Koch, et al.
Published: (2022-08-01)

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
by: Jui-Ling Yu, et al.
Published: (2023-02-01)

Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival
by: Howard L Kaufman, et al.
Published: (2024-04-01)

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002
by: Eric K. Ring, et al.
Published: (2017-12-01)

Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity
by: Jennifer L Leddon, et al.
Published: (2014-01-01)

Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
by: Dileep D. Monie, et al.
Published: (2021-05-01)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
by: Andrea Vannini, et al.
Published: (2023-08-01)

Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus
by: Jun Ding, et al.
Published: (2022-10-01)

Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia
by: Sara Shayan, et al.
Published: (2022-04-01)

Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma
by: Hao Yang, et al.
Published: (2022-04-01)

RPK 421 - Landskap
by: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Published: (1995)

Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.
by: Lili Gan, et al.
Published: (2014-01-01)

Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation
by: Kotaro Sugawara, et al.
Published: (2021-09-01)

Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy
by: Venkateswarlu Chamcha, et al.
Published: (2024-04-01)

Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency
by: Marine Ricordel, et al.
Published: (2018-07-01)